文献速递神经肿瘤小儿神经外科与脑积水

弥漫性内生型脑桥胶质瘤的诊断与治疗:现状如何?

Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
PubMed 文献 · J Neurooncol · 2019-09-14

该调查向欧洲DIPG专业医护人员发放在线问卷,评估诊断与进展期治疗策略。仅13.5%对所有患者活检,54.1%诊断时仅放疗;进展后不治疗倾向从1.4%升至77.0%,显示治疗异质性大。

要点

  • DIPG中位总生存约11个月,诊断与进展期治疗策略差异大。
  • 仅13.5%受访者对全部患者活检,41.9%不常活检。
  • 诊断时54.1%仅放疗,44.6%放疗联合化疗;进展后77.0%倾向不治疗。

核心结论

  • 调查显示DIPG治疗方案异质性大,尤其疾病进展期,需国际共识指南。

研究设计与样本

  • 向DIPG专业医护人员发放在线问卷,调查诊断时和疾病进展时的治疗策略。

主要发现

  • 13.5%受访者对全部患者活检,41.9%不常活检。
  • 诊断时54.1%仅放疗,44.6%放疗联合化疗。
  • 进展后不治疗倾向从诊断时1.4%升至第二次进展后77.0%。
  • 36.5%受访者在诊断时对小于3岁儿童采用不同治疗。
  • 51.4%受访者将少于25%的患者纳入临床试验。

临床怎么用

  • 调查提示DIPG诊断与治疗策略差异大,尤其进展期不治疗倾向高。
  • 多数受访者仅将少数患者纳入临床试验,需更多协作临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) is a rare clinically, neuro-radiologically, and molecularly defined malignancy of the brainstem with a median overall survival of approximately 11 months. Our aim is to evaluate the current tendency for its treatment in Europe in order to develop (inter)national consensus guidelines. METHODS: Healthcare professionals specialized in DIPG were asked to fill in an online survey with questions regarding usual treatment strategies at diagnosis and at disease progression in their countries and/or their centers, respectively. RESULTS: Seventy-four healthcare professionals responded to the survey, of which 87.8% were pediatric oncologists. Only 13.5% of the respondents biopsy all of their patients, 41.9% biopsy their patients infrequently. More than half of the respondents (54.1%) treated their patients with radiotherapy only at diagnosis, whereas 44.6% preferred radiotherapy combined with chemotherapy. When the disease progresses, treatment strategies became even more diverse, and the tendency for no treatment increased from 1.4% at diagnosis to 77.0% after second progression. 36.5% of the healthcare professionals treat children younger than 3 years differently than older children at diagnosis. This percentage decreased, when the disease progresses. Most of the participants (51.4%) included less than 25% of their patients in clinical trials. CONCLUSION: This survey demonstrates a large heterogeneity of treatment regimens, especially at disease progression. We emphasize the need for international consensus guidelines for the treatment of DIPG, possible by more collaborative clinical trials.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol. 2019. PMID: 31522324. doi:10.1007/s11060-019-03287-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。